

**CONTACT PERSON FOR MORE INFORMATION:** Joseph R. Coyne, Assistant to the Board; 202-452-3204.

**SUPPLEMENTARY INFORMATION:** You may call 202-452-3206 beginning at approximately 5 p.m. two business days before the meeting for a recorded announcement of bank and bank holding company applications scheduled for the meeting; or you may contact the Board's Web site at <http://www.bog.frb.fed.us> for an electronic announcement that not only lists applications, but also indicates procedural and other information about the meeting.

Dated: May 8, 1998.

**Jennifer J. Johnson,**

*Deputy Secretary of the Board.*

[FR Doc. 98-12656 Filed 5-8-98; 12:29 pm]

**BILLING CODE 6210-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

#### **Pfizer, Inc.; Withdrawal of Approval of NADA's**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is withdrawing approval of four new animal drug applications (NADA's) held by Pfizer, Inc. The NADA's provide for use of oxytetracycline hydrochloride. The sponsor requested the withdrawal of approval of the NADA's because the animal drug products are no longer manufactured or marketed.

**EFFECTIVE DATE:** May 12, 1998.

**FOR FURTHER INFORMATION CONTACT:** Dianne T. McRae, Center for Veterinary

Medicine (HFV-102), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-0212.

**SUPPLEMENTARY INFORMATION:** Pfizer, Inc., 235 East 42d St., New York, NY 10017 is the sponsor of NADA 8-696 TM-5 Antibiotic Feed Supplement (oxytetracycline), NADA 10-661 Terramycin Egg Formula (oxytetracycline hydrochloride), NADA 11-034 Liquimast Solution for Mastitis (oxytetracycline hydrochloride), and NADA 13-470 TM-10 Premix (oxytetracycline). The animal drug products were subject to review under the National Academy of Sciences/ National Research Council, Drug Efficacy Study Implementation Program, and are currently subject to requirements for finalization under that program. Pfizer, Inc., the current sponsor, requested withdrawal of approval of the NADA's because the animal drug products are no longer manufactured or marketed.

Therefore, under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Center for Veterinary Medicine (21 CFR 5.48), and in accordance with § 514.115 *Withdrawal of approval of applications* (21 CFR 514.115), notice is given that approvals of NADA's 8-696, 10-661, 11-034, 13-470, and all supplements and amendments thereto are hereby withdrawn, effective May 22, 1998.

These products had not been the subject of a regulation published under section 512 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b). Therefore, an amendment to the animal drug regulations to reflect the withdrawal of approvals is not required.

Dated: April 24, 1998.

**Stephen F. Sundlof,**

*Director, Center for Veterinary Medicine.*

[FR Doc. 98-12612 Filed 5-11-98; 8:45 am]

**BILLING CODE 4160-01-F**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. 98N-0285]

#### **Sanofi Pharmaceuticals, Inc., et al.; Withdrawal of Approval of 21 New Drug Applications and 62 Abbreviated New Drug Applications**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is withdrawing approval of 21 new drug applications (NDA's) and 62 abbreviated new drug applications (ANDA's). The holders of the applications notified the agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.

**EFFECTIVE DATE:** June 11, 1998.

**FOR FURTHER INFORMATION CONTACT:** Olivia A. Pritzlaff, Center for Drug Evaluation and Research (HFD-7), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-594-2041.

**SUPPLEMENTARY INFORMATION:** The holders of the applications listed in the table in this document have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications. The applicants have also, by their request, waived their opportunity for a hearing.

Application No.	Drug	Applicant
NDA 4-496	Pipanol Powder and Tablets (trihyphenidyl)	Sanofi Pharmaceuticals, Inc., 90 Park Ave., New York, NY 10016.
NDA 6-328	Isuprel (isoproterenol hydrochloride) Sublingual Tablets, 10 milligrams (mg) and 15 mg	Do.
NDA 7-514	Insulin, NPH Iletin	Eli Lilly and Co., Lilly Corporate Center, Indianapolis, IN 46285.
NDA 8-256	Insulin	Do.
NDA 8-717	Acetaminophen Tablets USP (acetaminophen tablets)	Roxane Laboratories, Inc., P.O. Box 16532, Columbus, OH 43216-6532.
NDA 8-847	Sucostrin (succinylcholine chloride injection)	Apothecon, Inc., P.O. Box 4500, Princeton, NJ 08543-4500.
NDA 8-983	Arfonad (trimethaphan camsylate) Ampules	Hoffmann-La Roche, Inc., 40 Kingsland St., Nutley, NJ 07110-1199.
NDA 9-088	Neothylline (dyphylline) injection	TEVA Pharmaceuticals USA (formerly Lemmon Co.), 650 Cathill Rd., Sellersville, PA 18960.
NDA 9-300	Insulin, Lente Iletin I	Eli Lilly and Co.
NDA 9-410	Lotusate Tablets and Capsules (talbutal)	Sanofi Pharmaceuticals, Inc.
NDA 9-479	Jayne's Liquid Vermifuge (piperazine hexahydrate)	Do.